Welcome to our dedicated page for CEREW news (Ticker: CEREW), a resource for investors and traders seeking the latest updates and insights on CEREW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CEREW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CEREW's position in the market.
Cerevel Therapeutics has secured up to $125 million in non-dilutive funding from NovaQuest and Bain Capital to finance the Phase 3 development of tavapadon for Parkinson's disease, enabling a planned NDA submission. The funding, received in four installments over four years, will not dilute existing shareholder equity. Cerevel retains significant upside potential from tavapadon sales and holds full worldwide rights. Preliminary data from ongoing TEMPO trials is anticipated in the first half of 2023, extending the company's cash runway into 2024.
Cerevel Therapeutics (Nasdaq: CERE) reported its fourth quarter and full year 2020 results on March 24, 2021. The company ended 2020 with $383.6 million in cash, substantially up from $79.6 million in 2019, thanks to a successful go-public transaction. R&D expenses rose to $103.3 million, driven by advancements in clinical trials for drug candidates like tavapadon and darigabat. Looking ahead, 2021 is positioned as a pivotal year with multiple clinical data readouts anticipated and R&D expenses expected to increase.
Cerevel Therapeutics (Nasdaq: CERE) will have its CEO, Tony Coles, participate in a fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 9:00 a.m. EDT. Investors can access the live webcast in the investor relations section of the Cerevel website. The company focuses on neuroscience diseases and has a diversified pipeline including five clinical-stage therapies for conditions like schizophrenia and epilepsy. Cerevel is committed to advancing its research and potential collaborations or acquisitions.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2020 financial results on March 24, 2021, before U.S. markets open. A conference call will follow at 8:00 a.m. EST to discuss the results and business updates. Interested parties can access the call via phone or through a live webcast on the company's investor site. Cerevel is focused on neuroscience diseases, with a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) will participate in the Cowen 41st Annual Health Care Conference on March 3, 2021. The presentation is scheduled for 11:00 a.m. EST and will be available via live webcast on their investor relations website. Cerevel specializes in neuroscience diseases and is advancing multiple clinical-stage therapies for conditions like Parkinson’s, epilepsy, and schizophrenia.
The company emphasizes its unique approach combining neurocircuitry knowledge with receptor selectivity.
Cerevel Therapeutics has announced that darigabat is now the international nonproprietary name for CVL-865, a Phase 2 GABA Positive Allosteric Modulator. The company is hosting a live R&D event to detail its ongoing Phase 2 trials for darigabat in drug-resistant focal epilepsy and acute anxiety. Cerevel plans to file U.S. IND applications in 2021 for its PDE4B and Kappa Opioid Receptor Agonist preclinical programs. Darigabat has been well-tolerated in previous trials, showing effectiveness in epilepsy treatment.
Cerevel Therapeutics has appointed Deval Patrick and Deborah Baron as independent members of its Board of Directors. Patrick, a former Massachusetts governor, brings expertise in the life sciences sector, while Baron serves as senior vice president at Pfizer, leading global business development. CEO Tony Coles expressed optimism about their contributions to Cerevel's goal of becoming a premier neuroscience company. Cerevel focuses on developing innovative treatments for conditions like Parkinson's disease and schizophrenia, boasting a diverse pipeline of clinical-stage therapies.
Cerevel Therapeutics will host a virtual R&D event on January 28, from 9:00 to 11:00 a.m. EST, focusing on CVL-865, a Phase 2 GABA positive allosteric modulator. The presentation will include insights into CVL-865 and preclinical programs.
CVL-865 is currently under investigation in two clinical trials: the REALIZE trial for drug-resistant focal onset seizures, with results expected in 2022, and a Phase 1 trial for acute anxiety, with results anticipated in 2021. The webcast will be available for replay for 90 days.
Cerevel Therapeutics (Nasdaq: CERE) has appointed Dr. Ruth McKernan as an independent board member. A seasoned expert in neuroscience, Dr. McKernan has over 25 years of experience in the pharmaceutical industry, including leadership roles at Pfizer and Merck. She currently works with SV Health Investors, focusing on neurodegenerative disorders. CEO Tony Coles believes her expertise will enhance Cerevel's innovation in therapies for diseases like schizophrenia and Parkinson's. Cerevel aims to establish itself as a premier neuroscience company.
Cerevel Therapeutics (Nasdaq: CERE) will host a live webcast on December 14 from 11:00 a.m. to noon EST, providing a corporate overview and a moderated Q&A session. Presenters include Tony Coles, Ray Sanchez, and John Renger, alongside Kathy Yi as part of the Q&A. Access to the live webcast will be available via the company’s investor relations website, with a replay for 90 days. Cerevel focuses on treating neuroscience diseases and has a pipeline of five clinical-stage therapies for conditions like schizophrenia and Parkinson’s disease.
